Despite this variability, treatment of MDM with anti-CCL2 Ab led to a significant decrease in the accumulation of HIV-1 DNA copies at both time points (Figure 3A), with a more profound reduction of viral DNA levels at 7 days post-infection. This evidence concerns the gene CCL2 and infection.